<DOC>
	<DOCNO>NCT01033344</DOCNO>
	<brief_summary>Cat allergy increasingly prevalent condition , affect 10-15 % patient allergic rhinoconjunctivitis and/or asthma . Cat-PAD novel , synthetic , allergen-derived peptide desensitise vaccine , currently develop treatment cat allergy . This study look efficacy , safety tolerability two dose Cat-PAD cat allergic subject follow challenge cat allergen EEC .</brief_summary>
	<brief_title>Cat-PAD Exposure Chamber Study</brief_title>
	<detailed_description>This study design randomise , double-blind , placebo-controlled , parallel group study evaluate safety tolerability Cat-PAD cat allergic subject allergic rhinoconjunctivitis , subject may also control asthma . The efficacy Cat-PAD explore subject use ( Environmental Exposure Chamber ) EEC . The study consist 3 study period . In Period 1 , Screening perform maximum 12 week randomisation may consist one two visit clinic , Investigator 's discretion . Baseline Challenge consist 4 visit EEC least 3 day randomisation . In Period 2 , subject cohort comply inclusion/exclusion criterion randomise one three group receive treatment every 2 week ( Â±2 day ) 14 week . In Period 3 , Post Treatment Challenge consist 4 visit EEC 18-22 week first administration treatment period assessment perform identical baseline challenge . Follow-up conduct 3-10 day PTC .</detailed_description>
	<criteria>Male female , age 1865 year Minimum 1year history rhinoconjunctivitis exposure cat . ( Subjects may also control asthma ) Positive skin prick test cat allergen wheal diameter least 3mm large produce negative control Minimum qualify rhinoconjunctivitis symptom score `` Partly control '' `` uncontrolled '' asthma History anaphylaxis cat allergen FEV1 le 70 % predicted Subjects tolerate baseline challenge EEC Treatment betablockers , Alphaadrenoceptor blocker , Tranquillizers psychoactive drug A history significant disease disorder ( e.g . cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , neoplastic/malignant , psychiatric , major physical impairment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Cat allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Exposure chamber</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Cat-PAD</keyword>
</DOC>